SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-012982 to Cultivauna, LLC (CIK 0001748885)

Cultivauna, LLC (CIK 0001748885)
Date: Nov. 29, 2023 · CIK: 0001748885 · Accession: 0000000000-23-012982

AI Filing Summary & Sentiment

Date
November 29, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Cultivauna, LLC (CIK 0001748885)

Letter

United States securities and exchange commission logo November 29, 2023 David Goubert President and Chief Executive Officer Ayr Wellness Inc. 2601 South Bayshore Drive, Suite 900 Miami, Florida 33133 Re:Ayr Wellness Inc. Application for Qualification of Indenture Under the Trust Indenture Act of 1939 on Form T-3 Filed November 22, 2023 File No. 022-29110 Dear David Goubert: This is to advise you that we have not reviewed and will not review your application. Please refer to Section 307(c) of the Trust Indenture Act regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Merritt S. Johnson

Show Raw Text
United States securities and exchange commission logo
November 29, 2023
David Goubert
President and Chief Executive Officer
Ayr Wellness Inc.
2601 South Bayshore Drive, Suite 900
Miami, Florida 33133
Re:Ayr Wellness Inc.
Application for Qualification of Indenture Under
the Trust Indenture Act of 1939 on Form T-3
Filed November 22, 2023
File No. 022-29110
Dear David Goubert:
            This is to advise you that we have not reviewed and will not review your application.
            Please refer to Section 307(c) of the Trust Indenture Act regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Merritt S. Johnson